Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice

William Stohl, Ning Yu, Samantha A. Chalmers, Chaim Putterman, Chaim O. Jacob

Research output: Contribution to journalArticle

Abstract

Background/objective Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To begin to address this, we generated SLE-prone NZM 2328 mice with lifelong reduction in CTLA-4 expression. Methods Since CTLA-4-deficient (Ctla4 -/- ) NZM mice developed a lethal lymphoproliferative disorder by 3-6 weeks of age, development of SLE in these mice could not be studied. Ctla4 haploinsufficient NZM.Ctla4 +/- mice were assessed in parallel with littermate female NZM.Ctla4 +/+ mice. Evaluations included CTLA-4 expression and lymphocyte profiles, assessed by fluorescence-activated cell sorting; serological profiles, assessed by ELISA; renal immunopathology, assessed by histology and immunofluorescence; and clinical courses, assessed by mortality. Results CTLA-4 expression was lower in NZM.Ctla4 +/- mice than in NZM.Ctla4 +/+ mice. Spleen mononuclear cells, B cells, plasma cells, CD4 + cells, recently activated CD4 + cells and CD4 + T regulatory (Treg) cells were increased in NZM.Ctla4 +/- mice (p≤0.042). The serological profile, degree of renal immunopathology and mortality in NZM.Ctla4 +/- mice remained unaffected. Conclusion Lifelong reduction in CTLA-4 expression in NZM mice neither accelerated nor aggravated SLE. Expansion in Treg cells may have played a protective role. Our observations raise the hope that long-term treatment of patients with SLE with an anti-CTLA-4 agent, should the need arise, would not adversely affect SLE disease activity.

Original languageEnglish (US)
Article number000313
JournalLupus Science and Medicine
Volume6
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Regulatory T-Lymphocytes
Kidney
Lymphoproliferative Disorders
Mortality
Plasma Cells
Fluorescent Antibody Technique
Histology
Flow Cytometry
B-Lymphocytes
Therapeutics
Spleen
Enzyme-Linked Immunosorbent Assay
Lymphocytes

Keywords

  • animal model
  • checkpoint protein
  • CTLA-4
  • lupus

ASJC Scopus subject areas

  • Immunology

Cite this

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice. / Stohl, William; Yu, Ning; Chalmers, Samantha A.; Putterman, Chaim; Jacob, Chaim O.

In: Lupus Science and Medicine, Vol. 6, No. 1, 000313, 01.02.2019.

Research output: Contribution to journalArticle

Stohl, William ; Yu, Ning ; Chalmers, Samantha A. ; Putterman, Chaim ; Jacob, Chaim O. / Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice. In: Lupus Science and Medicine. 2019 ; Vol. 6, No. 1.
@article{afee2b05cb6344f5a30a0a241d7b623a,
title = "Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice",
abstract = "Background/objective Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To begin to address this, we generated SLE-prone NZM 2328 mice with lifelong reduction in CTLA-4 expression. Methods Since CTLA-4-deficient (Ctla4 -/- ) NZM mice developed a lethal lymphoproliferative disorder by 3-6 weeks of age, development of SLE in these mice could not be studied. Ctla4 haploinsufficient NZM.Ctla4 +/- mice were assessed in parallel with littermate female NZM.Ctla4 +/+ mice. Evaluations included CTLA-4 expression and lymphocyte profiles, assessed by fluorescence-activated cell sorting; serological profiles, assessed by ELISA; renal immunopathology, assessed by histology and immunofluorescence; and clinical courses, assessed by mortality. Results CTLA-4 expression was lower in NZM.Ctla4 +/- mice than in NZM.Ctla4 +/+ mice. Spleen mononuclear cells, B cells, plasma cells, CD4 + cells, recently activated CD4 + cells and CD4 + T regulatory (Treg) cells were increased in NZM.Ctla4 +/- mice (p≤0.042). The serological profile, degree of renal immunopathology and mortality in NZM.Ctla4 +/- mice remained unaffected. Conclusion Lifelong reduction in CTLA-4 expression in NZM mice neither accelerated nor aggravated SLE. Expansion in Treg cells may have played a protective role. Our observations raise the hope that long-term treatment of patients with SLE with an anti-CTLA-4 agent, should the need arise, would not adversely affect SLE disease activity.",
keywords = "animal model, checkpoint protein, CTLA-4, lupus",
author = "William Stohl and Ning Yu and Chalmers, {Samantha A.} and Chaim Putterman and Jacob, {Chaim O.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1136/lupus-2018-000313",
language = "English (US)",
volume = "6",
journal = "Lupus Science and Medicine",
issn = "2053-8790",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice

AU - Stohl, William

AU - Yu, Ning

AU - Chalmers, Samantha A.

AU - Putterman, Chaim

AU - Jacob, Chaim O.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background/objective Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To begin to address this, we generated SLE-prone NZM 2328 mice with lifelong reduction in CTLA-4 expression. Methods Since CTLA-4-deficient (Ctla4 -/- ) NZM mice developed a lethal lymphoproliferative disorder by 3-6 weeks of age, development of SLE in these mice could not be studied. Ctla4 haploinsufficient NZM.Ctla4 +/- mice were assessed in parallel with littermate female NZM.Ctla4 +/+ mice. Evaluations included CTLA-4 expression and lymphocyte profiles, assessed by fluorescence-activated cell sorting; serological profiles, assessed by ELISA; renal immunopathology, assessed by histology and immunofluorescence; and clinical courses, assessed by mortality. Results CTLA-4 expression was lower in NZM.Ctla4 +/- mice than in NZM.Ctla4 +/+ mice. Spleen mononuclear cells, B cells, plasma cells, CD4 + cells, recently activated CD4 + cells and CD4 + T regulatory (Treg) cells were increased in NZM.Ctla4 +/- mice (p≤0.042). The serological profile, degree of renal immunopathology and mortality in NZM.Ctla4 +/- mice remained unaffected. Conclusion Lifelong reduction in CTLA-4 expression in NZM mice neither accelerated nor aggravated SLE. Expansion in Treg cells may have played a protective role. Our observations raise the hope that long-term treatment of patients with SLE with an anti-CTLA-4 agent, should the need arise, would not adversely affect SLE disease activity.

AB - Background/objective Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To begin to address this, we generated SLE-prone NZM 2328 mice with lifelong reduction in CTLA-4 expression. Methods Since CTLA-4-deficient (Ctla4 -/- ) NZM mice developed a lethal lymphoproliferative disorder by 3-6 weeks of age, development of SLE in these mice could not be studied. Ctla4 haploinsufficient NZM.Ctla4 +/- mice were assessed in parallel with littermate female NZM.Ctla4 +/+ mice. Evaluations included CTLA-4 expression and lymphocyte profiles, assessed by fluorescence-activated cell sorting; serological profiles, assessed by ELISA; renal immunopathology, assessed by histology and immunofluorescence; and clinical courses, assessed by mortality. Results CTLA-4 expression was lower in NZM.Ctla4 +/- mice than in NZM.Ctla4 +/+ mice. Spleen mononuclear cells, B cells, plasma cells, CD4 + cells, recently activated CD4 + cells and CD4 + T regulatory (Treg) cells were increased in NZM.Ctla4 +/- mice (p≤0.042). The serological profile, degree of renal immunopathology and mortality in NZM.Ctla4 +/- mice remained unaffected. Conclusion Lifelong reduction in CTLA-4 expression in NZM mice neither accelerated nor aggravated SLE. Expansion in Treg cells may have played a protective role. Our observations raise the hope that long-term treatment of patients with SLE with an anti-CTLA-4 agent, should the need arise, would not adversely affect SLE disease activity.

KW - animal model

KW - checkpoint protein

KW - CTLA-4

KW - lupus

UR - http://www.scopus.com/inward/record.url?scp=85062464059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062464059&partnerID=8YFLogxK

U2 - 10.1136/lupus-2018-000313

DO - 10.1136/lupus-2018-000313

M3 - Article

VL - 6

JO - Lupus Science and Medicine

JF - Lupus Science and Medicine

SN - 2053-8790

IS - 1

M1 - 000313

ER -